Who owns Hemab Therapeutics?

Hemab Therapeutics is currently owned by Sofinnova Partners, through Sofinnova Crossover Fund I, since 2020.

When did Sofinnova Partners acquire Hemab Therapeutics?

Sofinnova Partners acquired Hemab Therapeutics in 2020 (active for 6 years).

Home/Companies/Biotech/Hemab Therapeutics

Hemab Therapeutics

Biotech·

Denmark·Active·6yr hold

Hemab Therapeutics is a healthcare / biotech company, headquartered in Denmark.

Entry

2020

Hold

6yr

Status

Active

Est. EV

–

Investor

Sofinnova Partners

Key facts

HQDenmark

SectorHealthcare / Biotech

Danish-US clinical biotech developing prophylactic therapeutics for rare, underserved bleeding and thrombotic disorders.

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Start free

Already a member? Sign in

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Last updated April 2026 · Sourced from public filings